Drug Profile
Research programme: anti-infectives - sanofi-aventis/Schering-Plough
Latest Information Update: 16 Aug 2007
Price :
$50
*
At a glance
- Originator sanofi-aventis; Schering-Plough
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 18 Apr 2002 Preclinical trials in Bacterial infections in USA (unspecified route)